References
- Bilici A, Selcukbiricik F, Demir, et al (2014). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Asian Pac J Cancer Prev, 15, 8661-6. https://doi.org/10.7314/APJCP.2014.15.20.8661
- Bayoglu IV, Varol U, Yildiz I, et al (2014). Second-Line capecitabine and oxaliplatin combination for gemcitabineresistant advanced pancreatic cancer. Asian Pac J Cancer Prev, 15, 7119-23. https://doi.org/10.7314/APJCP.2014.15.17.7119
- Cassidy J, Twelves C, Van Cutsem E, et al (2002). First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol, 13, 566-75. https://doi.org/10.1093/annonc/mdf089
- Cassidy J, Clarke S, Diaz-Rubio E, et al (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol, 26, 2006-12. https://doi.org/10.1200/JCO.2007.14.9898
- Cassidy J, Clarke S, Diaz-Rubio E, et al (2011). XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer, 105, 58-64. https://doi.org/10.1038/bjc.2011.201
- Choi JG, Seo JH, Oh SC, et al (2012). A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Cancer Res Treat, 44, 127-32. https://doi.org/10.4143/crt.2012.44.2.127
- Chua DT, Sham JS, Au GK (2003). A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy. Oral Oncol, 39, 361. https://doi.org/10.1016/S1368-8375(02)00120-3
- Chua D, Wei WI, Sham JS, et al (2008). Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol, 38, 244-9. https://doi.org/10.1093/jjco/hyn022
- Chua DT, Yiu HH, Seetalarom K, et al (2012). Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. Head Neck, 34, 1225-30. https://doi.org/10.1002/hed.21884
- Chiu J, Tang V, Leung R, et al (2014). Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev, 14, 6585-90.
- Ciuleanu E, Irimie A, Ciuleanu TE, et al (2008). Capecitabine as salvage treatment in relapsed nasopharyngeal carcinoma: a phase II study. J Buon, 13, 37-42.
- Comella P, Massidda B, Filippelli G, et al (2009). Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol, 135, 217-26. https://doi.org/10.1007/s00432-008-0454-7
- Cunningham D, Starling N, Rao S, et al (2008). Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 358, 36-46. https://doi.org/10.1056/NEJMoa073149
- de Naurois J, Novitzky-Basso I, Gill MJ, et al (2010). Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol, 21, 252-6. https://doi.org/10.1093/annonc/mdq196
- Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al (2007). Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as firstline therapy in metastatic colorectal cancer: final report of the spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol, 25, 4224-30. https://doi.org/10.1200/JCO.2006.09.8467
- Ducreux M, Bennouna J, Hebbar M, et al (2011). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus ox-aliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer, 128, 682-90. https://doi.org/10.1002/ijc.25369
- Goldberg RM, Sargent DJ, Morton RF, et al (2004). A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22, 23-30. https://doi.org/10.1200/JCO.2004.09.046
- Jenkins AD, Ramondetta LM, Sun C, et al (2005). Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol, 97, 840-4. https://doi.org/10.1016/j.ygyno.2005.02.029
- Kang YK, Kang WK, Shin DB, et al (2009). Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 20, 666-73. https://doi.org/10.1093/annonc/mdn717
- Li YH, Wang FH, Jiang WQ, et al (2008). Phase II study of capecitabine and cisplatin combination as firstline chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol, 62, 539-44. https://doi.org/10.1007/s00280-007-0641-2
- Louvet C, Andre T, Tigaud JM, et al (2002). Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol, 20, 4543-8. https://doi.org/10.1200/JCO.2002.02.021
- Martinez-Trufero J, Isla D, Adansa JC, et al (2010). Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer, 102, 1687. https://doi.org/10.1038/sj.bjc.6605697
- Miwa M, Ura M, Nishida M et al (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34, 1274-81. https://doi.org/10.1016/S0959-8049(98)00058-6
- Okines AF, Norman AR, McCloud P, et al (2009). Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabinebased combination chemotherapy and infused 5-fluorouracilbased combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol, 20, 1529-34. https://doi.org/10.1093/annonc/mdp047
- Rougier P, Mitry E, Cunningham D, et al (2003). Is age a prognostic factor of toxicity and efficacy in patients (pts) with metastatic colorectal cancer (MCRC) receiving irinotecan in combination with 5FU/folinic acid (FA). Proc Am Soc Clin Oncol, 22, 267
- Scheithauer W, Mckendrick, Begbie S, et al (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol, 14, 1735-43. https://doi.org/10.1093/annonc/mdg500
- Stockler MR, Harvey VJ, Francis PA, et al (2011). Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol, 29, 4498-504. https://doi.org/10.1200/JCO.2010.33.9101
- Sym SJ, Chang HM, Ryu MH, et al (2010). Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. Ann Surg Oncol, 17, 1024-32. https://doi.org/10.1245/s10434-009-0838-1
- Twelves C, Wong A, Nowacki PN et al (2005). Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med, 352, 2696-704. https://doi.org/10.1056/NEJMoa043116
- Van Cutsem E, Twelves C, Cassidy J, et al (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 19, 4097-106. https://doi.org/10.1200/JCO.2001.19.21.4097
- Van Cutsem E, Hoff PM, Harper P, et al (2004). Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer, 90, 1190-7. https://doi.org/10.1038/sj.bjc.6601676
- Wadell TS, Chau I, Barbachano Y, et al (2012). A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol, 30, 18.
- Varol U, Dirican A, Yildiz I, et al (2014). First-line monochemotherapy in frail elderly patients with metastatic colorectal cancer. Asian Pac J Cancer Prev, 15, 3157-61. https://doi.org/10.7314/APJCP.2014.15.7.3157
-
Vasey PA, McMahon L, Paul J, et al (2003). A phase II trial of capecitabine (Xeloda
$^{(R)}$ ) in recurrent ovarian cancer. British J Cancer, 89, 1843-8. https://doi.org/10.1038/sj.bjc.6601381 - Xiong HQ, Varadhachary GR, Blais JC, et al (2008). Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as secondline therapy for patients with advanced pancreatic cancer. Cancer, 113, 2046-52. https://doi.org/10.1002/cncr.23810
- Yoney A, Isikli L (2013). Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? Asian Pac J Cancer Prev, 14, 5127-31. https://doi.org/10.7314/APJCP.2013.14.9.5127